Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 6/2015

01-06-2015 | Research Article

Effects of zoledronate on the radiation-induced collagen breakdown: a prospective randomized clinical trial

Authors: M. Gierloff, M. Reutemann, A. Gülses, P. Niehoff, J. Wiltfang, Y. Açil

Published in: Clinical and Translational Oncology | Issue 6/2015

Login to get access

Abstract

Background

A negative side effect of therapeutic irradiation is the radiation-induced bone loss which can lead, in long term, to pathological fractures. Until today, the detailed mechanism is unknown. If osteoclasts would mainly contribute to the pathological bone loss, bisphosphonates could potentially counteract the osteolytic process and possibly help to prevent long-term complications. The aim of this study was to evaluate the effect of zoledronic acid on the early radiation-induced degradation of bone collagen fibrils by monitoring the urinary excretion of hydroxylysylpyridinoline and lysylpyridinoline under radiotherapy.

Patients and methods

A total of 40 patients with skeletal metastases were assigned for a local radiotherapy and bisphosphonate treatment. The patients were prospectively randomized into two treatment groups: group A (n = 20) received the first zoledronate administration after and group B (n = 20) prior to the radiotherapy. Urine samples were collected from each patient on the first day, in the middle, and on the last day of the radiation therapy. Measurement of the bone metabolites hydroxylysylpyridinoline and lysylpyridinoline was performed by high-performance liquid chromatography. Statistical analysis was performed using the Mann–Whitney U test.

Results

The hydroxylysylpyridinoline and lysylpyridinoline excretion decreased significantly in the combined bisphosphonate and radiotherapy group (p = 0.02, p = 0.08). No significant change of the hydroxylysylpyridinoline and lysylpyridinoline excretion was determined in the patients that received solely irradiation.

Conclusion

The results indicate the ability of zoledronate to prevent the early radiation-induced bone collagen degradation suggesting that the radiation-induced bone loss is mainly caused by osteoclastic bone resorption rather than by a direct radiation-induced damage.
Literature
1.
Freundt K, Meyners T, Bajrovic A, Basic H, Karstens JH, Adamietz IA, et al. Radiotherapy for oligometastatic disease in patients with spinal cord compression (MSCC) from relatively radioresistant tumors. Strahlenther Onkol. 2010;186:218–23.CrossRefPubMed
2.
Sauer N, Leising D, Wild B, Treiber M, Henningsen P, Jakobsen T. Pain and quality of life following palliative radiotherapy of bone metastases. Strahlenther Onkol. 2006;182:550–6.CrossRefPubMed
3.
van Oorschot B, Schuler M, Simon A, Schleicher U, Geinitz H. Patterns of care and course of symptoms in palliative radiotherapy: a multicenter pilot study analysis. Strahlenther Onkol. 2011;187:461–6.CrossRefPubMed
4.
Mose S, Pfitzner D, Rahn A, Nierhoff C, Schiemann M, Bottcher HD. Role of radiotherapy in the treatment of multiple myeloma. Strahlenther Onkol. 2000;176:506–12.CrossRefPubMed
5.
Ogino I, Okamato N, Ono Y, Kitamura T, Nakayama H. Pelvic insuffiency fractures in postmenopausal woman with advanced cervical cancer treated by radiotherapy. Radiother Oncol. 2003;68:61–7.CrossRefPubMed
6.
Schmeler KM, Jhingran A, Iyer RB, Sun CC, Eifel PJ, Soliman PT, et al. Pelvic fractures after radiotherapy for cervical cancer: implications for survivors. Cancer. 2010;116:625–30.CrossRefPubMed
7.
Stanic S, Bolke TP, Rule WG, Timmermann RD. Rib fracture following stereotactic body radiotherapy: a potential pitfall. Clin Nucl Med. 2011;36:168–70.CrossRef
8.
Dudziak ME, Saadeh PB, Mehrara BJ, Steinbrech DS, Greenwald JA, Gittes GK, et al. The effects of ionizing radiation on osteoblast-like cells in vitro. Plast Reconstr Surg. 2000;106:1049–61.CrossRefPubMed
9.
Ural AU, Avcu F, Baran Y. Bisphosphonate treatment and radiotherapy in metastatic breast cancer. Med Oncol. 2008;25:350–5.CrossRefPubMed
10.
Szymcyk KH, Shapiro IM, Adams CS. Ionizing radiation sensitizes bone cells to apoptosis. Bone. 2004;34:148–56.CrossRef
11.
Willey JS, Lloyd SA, Robbins ME, Bourland JD, Smith-Sielicki H, Bowman LC, et al. Early increase in osteoclast number in mice after whole-body irradiation with 2 Gy X rays. Radiat Res. 2008;170:388–92.CrossRefPubMedCentralPubMed
12.
Williams HJ, Davies AM. The effect of X-rays on bone: a pictorial review. Eur Radiol. 2006;16:619–33.CrossRefPubMed
13.
Jereczek-Fossa BA, Orecchia R. Radiotherapy-induced mandibular bone complications. Cancer Treat Rev. 2002;28:65–74.CrossRefPubMed
14.
Açil Y, Springer IN, Niehoff P, Gassling V, Warnke PH, Açmaz S, et al. Proof of direct radiogenic destruction of collagen in vitro. Strahlenther Onkol. 2007;183:374–9.CrossRefPubMed
15.
Inoue Y, Miki C, Ojima E, Nomoto J, Kusunoki M. Pelvic insufficiency factures after preoperative radiotherapy for rectal carcinoma. Int J Clin Oncol. 2003;8:336–9.CrossRefPubMed
16.
Niehoff P, Wiltfang J, Springer IN, Weppner N, Kimmig B, Açil Y. Increased excretion of collagen crosslinks in irradiated patients indicates destruction of collagen. Int J Radiat Biol. 2006;82:503–9.CrossRefPubMed
17.
Springer ING, Terheyden H, Dunsche A, Czech N, Tiemann M, Hedderich J, et al. Collagen crosslink excretion and staging of oral cancer. Br J Cancer. 2003;88:1105–10.CrossRefPubMedCentralPubMed
18.
Burr DB. The contribution of the organic matrix to bone’s material properties. Bone. 2002;31:8–11.CrossRefPubMed
19.
Kini U, Nandeesh BN. Physiology of boneformation, remodelling and metabolism. In: Fogelman I, Gnanasegaran G, van der Wall H, editors. Radionuclideand hybrid bone imaging, vol. XIV. 2012. p. 29–57.CrossRef
20.
Rogers MJ, Crockett JC, Coxon FP, Mönkkönen J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone. 2011;49:34–41.CrossRefPubMed
21.
Coleman RE. Metastatic bone disease: clinical features, pathophysiology, and treatment strategies. Cancer Treat Rev. 2001;27:165–76.CrossRefPubMed
22.
23.
Goldhahn J, Feron JM, Kanis J, Papaloulos S, Reginster JY, Rizzoli R, et al. Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper. Calcif Tissue Int. 2012;90:343–53.CrossRefPubMed
24.
Rauch F, Travers R, Plotkin H, Glorieux FH. The effects of intravenous pamidronate on the bone tissue of children and adolescent with osteogenesis imperfecta. J Clin Invest. 2002;110:1293–9.CrossRefPubMedCentralPubMed
25.
Hoskin PJ. Bisphosphonates and radiation therapy for palliation of metastatic bone disease. Cancer Treat Rev. 2003;29:321–7.CrossRefPubMed
26.
Willey JS, Livingston EW, Robbings ME, Bourland JD, Tirado-Lee L, Smith-Sielicki H, et al. Risedronate prevents early radiation-induced osteoporosis in mice at multiple skeletal locations. Bone. 2010;46:101–11.CrossRefPubMedCentralPubMed
27.
Açil Y, Gierloff M, Behrens C, Möller B, Gassling V, Niehoff P, et al. Effects of zoledronate on irradiated bone in vivo: analysis of the collagen types I, V and their crosslinks lysylpyridinoline, hydroxylysylpyridinoline and hydroxyproline. Calcif Tissue Int. 2013;92:251–60.CrossRefPubMed
28.
Springer ING, Wiltfang J, Dunsche A, Lier GC, Bartsch M, Warnke PH, et al. A new method of monitoring osteomyelitis. Int J Oral Maxillofac Surg. 2007;36:527–32.CrossRefPubMed
29.
Hoskin PJ, Stratford MR, Folkes LK, Regan J, Yarnold JR. Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity. Lancet. 2000;355:1428–9.CrossRefPubMed
30.
Theriault RL, Theriault RL. Biology of bone metastases. Cancer Control. 2012;19:92–101.PubMed
31.
Arrington SA, Fisher ER, Willick GE, Mann KA, Allen MJ. Anabolic and antiresorptive drugs improve trabecular microarchitecture and reduce fracture risk following radiation therapy. Calcif Tissue Int. 2010;87:263–72.CrossRefPubMed
32.
Hui SK, Fairchild GR, Kidder LS, Sharma M, Bhattacharya M, Jackson S, et al. Skeletal remodeling following clinically relevant radiation-induced bone damage treated with zoledronic acid. Calcif Tissue Int. 2012;90:40–9.CrossRefPubMed
33.
Krempien R, Huber PE, Harms W, Treiber M, Wannenmacher M, Krempien B. Combination of early bisphosphonate administration and irradiation leads to improved remineralization and restabilization of osteolytic bone metastases in an animal tumor model. Cancer. 2003;98:1318–24.CrossRefPubMed
Metadata
Title
Effects of zoledronate on the radiation-induced collagen breakdown: a prospective randomized clinical trial
Authors
M. Gierloff
M. Reutemann
A. Gülses
P. Niehoff
J. Wiltfang
Y. Açil
Publication date
01-06-2015
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 6/2015
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-014-1257-8

Other articles of this Issue 6/2015

Clinical and Translational Oncology 6/2015 Go to the issue

Research Article

CMTM5 is reduced in prostate cancer and inhibits cancer cell growth in vitro and in vivo

Research Article

The clinical pathological significance of FRAT1 and ROR2 expression in cartilage tumors

Research Article

The NanoString-based multigene assay as a novel platform to screen EGFR, HER2, and MET in patients with advanced gastric cancer

Correspondence

Current radiation therapy techniques for lung cancer and its importance for suitable radiological assessment of treatment response in lung cancer

Research Article

Involvement of RalB in the effect of geranylgeranyltransferase I on glioma cell migration and invasion

Research Article

A new tumor biomarker, serum protein peak at 3,144 m/z, in patients with node-positive breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits